Risk of CNS relapse in DLBCL treated with R-CHOP(-like) chemotherapy using the CNS-IPI
| Study cohort . | Number of patients . | 2-y risk of CNS relapse . | |||
|---|---|---|---|---|---|
| Overall (all DLBCL) . | Low (0-1 factors) . | Intermediate (2-3 factors) . | High (4-5 factors) . | ||
| DSHNHL (7) | 2164* | 4% | 0.6% | 3.4% | 10.2% |
| BCCA (7) | 1597 | 4% | 0.8% | 3.9% | 12% |
| Danish (9) | 1532 | 4% (3 y) | 0.4% (3 y) | 3% (3 y) | 11% (3 y) |
| Study cohort . | Number of patients . | 2-y risk of CNS relapse . | |||
|---|---|---|---|---|---|
| Overall (all DLBCL) . | Low (0-1 factors) . | Intermediate (2-3 factors) . | High (4-5 factors) . | ||
| DSHNHL (7) | 2164* | 4% | 0.6% | 3.4% | 10.2% |
| BCCA (7) | 1597 | 4% | 0.8% | 3.9% | 12% |
| Danish (9) | 1532 | 4% (3 y) | 0.4% (3 y) | 3% (3 y) | 11% (3 y) |
*DLBCL n = 1735 (80%); sensitivity analysis produced similar results.